Spotlight On: Biosimilar Litigations - May 2026

Why It Matters

Understanding the precise scope of biosimilar litigation helps pharmaceutical companies assess risk, allocate resources, and craft defensible market entry strategies. Misclassifying a dispute could lead to costly procedural errors or missed enforcement opportunities.

Key Takeaways

• Biosimilar disputes involve reference product sponsors and rival biosimilar makers
• Litigation excludes reference‑only conflicts and university‑sponsor disputes
• Manufacturing‑patent fights like Cabilly patents are omitted from scope
• Legal updates serve as general guidance, not specific advice
• Venable LLP stresses need for tailored legal counsel

Pulse Analysis

The biosimilar sector has surged as biologics lose patent protection, prompting a wave of follow‑on products that promise lower costs. Yet, the promise of market share comes with a complex legal landscape where patent infringement, exclusivity periods, and regulatory pathways intersect. By clarifying which cases fall under the umbrella of "biosimilar litigations," Venable LLP equips stakeholders with a roadmap to navigate these disputes, ensuring they focus on the most consequential battles rather than peripheral patent arguments.

In practice, the distinction matters because litigation strategy and resource allocation differ dramatically between a direct biosimilar‑to‑reference challenge and a broader manufacturing‑patent fight. Companies that mistakenly pursue a Cabilly‑type patent claim may expend significant legal fees without advancing their core product launch. Conversely, recognizing that a dispute with a rival biosimilar applicant is covered enables firms to leverage settlement opportunities, cross‑licensing, or defensive filings that protect market entry timelines.

The update’s disclaimer underscores a critical industry reality: biosimilar litigation is highly fact‑specific, and generic guidance cannot replace counsel attuned to a company’s portfolio and jurisdictional nuances. As the FDA continues to refine its pathways for interchangeable biologics, firms must pair strategic legal insight with robust regulatory intelligence. Tailored advice not only mitigates litigation risk but also positions companies to capitalize on the growing demand for affordable biologic therapies, ultimately shaping competitive dynamics across the U.S. healthcare market.